The STOP-HPV Trial 2: Performance Feedback Intervention
STOP-HPV
Improving HPV Vaccination Delivery in Pediatric Primary Care: The STOP-HPV Trial 2 Comparison of Performance Feedback (in the Presence of Communication Skills) and Standard of Care
2 other identifiers
interventional
48
1 country
1
Brief Summary
Most adolescents who receive human papillomavirus (HPV) vaccine are vaccinated in pediatric practices, yet missed opportunities (MOs) for HPV vaccination occur often and lead to low HPV vaccination rates. This cluster randomized clinical trial (RCT) will test the effectiveness (and cost-effectiveness) of the addition of performance feedback (period 2) to training providers previously received on HPV vaccine communication (period 1) to reduce MOs and increase HPV vaccination rates.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 29, 2018
CompletedFirst Posted
Study publicly available on registry
July 26, 2018
CompletedStudy Start
First participant enrolled
August 7, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 11, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 6, 2020
CompletedApril 30, 2020
April 1, 2020
1.5 years
June 29, 2018
April 29, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Change in the rate of missed vaccination opportunities among all clinicians
Change in the rate of missed vaccination opportunities from baseline (period 0) through the end of period 2 among all clinicians, with a focus on the contrast between the end of period 1 and period 2.
Monthly for Period 2 and also aggregated over the 6-month period from start date, where start date is site specific and depends on study decision on completion of training and readiness of site to proceed.
Change in the rate of missed vaccination opportunities among consenting clinicians
Change in the rate of missed vaccination opportunities from baseline (period 0) through the end of period 2 among consenting clinicians, with a focus on the contrast between periods 1 and 2.
Monthly for Period 2 and also aggregated over the 6-month period from start date, where start date is site specific and depends on study decision on completion of training and readiness of site to proceed.
Study Arms (2)
Intervention
EXPERIMENTALArm 1 will receive the STOP-HPV performance feedback intervention
Control
NO INTERVENTIONArm 2 will receive standard of care
Interventions
This intervention will be the addition of performance feedback (in the presence of communication skills).
Eligibility Criteria
You may qualify if:
- The practice provides HPV vaccination services to adolescents.
- The practice is part of Physician's Computer Company (PCC), Office Practicum (OP) or (a) yet-to-be selected health system(s).
- The practice has had the same EHR system in place for a year or more (with special consideration on a case by case basis if they are close to but not do not reach a year).
- The practice agrees to not participate in other HPV-related QI projects or research interventions during the study period (with special consideration on a case by case basis).
You may not qualify if:
- The practice plans to change EHR systems in the next three years.
- The practice participated in the last year, is currently engaged in, or plans to participate in an office-based HPV-related quality improvement (QI) project or research intervention during the study period (with special consideration on a case by case basis).
- Estimated 20% or more of adolescents at the practice receive HPV vaccinations at schools or health department clinics (given standard practice and published data, the investigators expect that few to no practices will need to be excluded based on this restriction).
- All patients of participating practices (intervention and comparison) aged 11-17 years who have at least 1 visit to the practice within the past two years.
- None apart from age of patients (above).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of California, Los Angeleslead
- Children's Hospital of Philadelphiacollaborator
- American Academy of Pediatricscollaborator
- University of Pennsylvaniacollaborator
- National Institutes of Health (NIH)collaborator
- National Cancer Institute (NCI)collaborator
- University of Rochestercollaborator
Study Sites (1)
American Academy of Pediatrics
Itasca, Illinois, 60143, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Peter Szilagyi, MD
University of California, Los Angeles
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Pediatrics, Executive Vice-Chair and Vice-Chair for Research, Department of Pediatrics
Study Record Dates
First Submitted
June 29, 2018
First Posted
July 26, 2018
Study Start
August 7, 2018
Primary Completion
February 11, 2020
Study Completion
March 6, 2020
Last Updated
April 30, 2020
Record last verified: 2020-04
Data Sharing
- IPD Sharing
- Will not share